CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net loss	$ (27,342)	$ (30,784)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	541	588
Amortization of debt discount and debt issuance costs	0	1,873
Share-based compensation expense	5,389	1,522
Other adjustments	(719)	(1)
Net changes in assets and liabilities
Accounts receivable	(10,589)	0
Inventories	(1,260)	0
Prepaid expenses and other current assets	(6,093)	(4,131)
Research and development tax credit receivable	(17)	0
Accounts payable & other current liabilities	7,528	468
Accrued expenses	3,415	348
Other assets and liabilities	(557)	(116)
Net cash used in operating activities	(29,704)	(30,233)
Cash flows from investing activities:
Proceeds from sales of marketable securities	119,066	15,295
Purchases of marketable securities	(97,679)	(10,229)
Net cash provided by investing activities	21,387	5,066
Cash flows from financing activities:
Proceeds received in advance of Series B Preferred Shares Issuance	0	40,000
Payments for February 2023 Notes	0	(17,500)
Proceeds from issuance of shares off the at-the-market offering program	9,250	11,913
Proceeds from stock option exercises and employee share purchase plan	3,940	29
Net cash provided by financing activities	13,190	34,442
Effect of foreign currency exchange rate changes on cash and cash equivalents	(246)	135
Net change in cash and cash equivalents	4,627	9,410
Cash and cash equivalents at January 1,	31,167	73,981
Cash and cash equivalents at March 31,	35,794	83,391
Supplemental disclosures of cash flow information:
Interest paid	$ 730	$ 3,050